Introduction {#S1}
============

*Streptomyces*, Gram-positive mycelial bacteria with high GC content, shows a complex morphological differentiation and belongs to actinobacteria ([@B40]). It is reported that 61% of so far discovered microorganism-derived bioactive substances are produced by actinobacteria (mainly *Streptomyce*). Most of the clinically essential drugs containing antibiotic and other bio-active agents are derived from *Streptomyces* ([@B126]). In the past decades, scientists have made great advances to elucidate the regulatory mechanisms related to antibiotic production in *Streptomyces*. Generally, the antibiotic production is stringently and elaborately regulated by pyramidal transcriptional regulatory cascades, including signaling pathways, global regulators, pathway-specific regulator (PSR), and feedback regulation. This interweaved networks can determine the production levels of antibiotic under specific culture condition ([@B13]).

With the accumulation of genome data, the number of predicted secondary biosynthetic gene clusters (SBGs) on genome is much more than that of the products has been identified. Generally, most of these gene clusters have been defined as cryptic ones because of unknown or undetectable secondary metabolites. Scientists proposed that the *Streptomyces* has been greatly underestimated for the capability to produce diversity of natural products ([@B5], [@B6]). Up to now, *Streptomyces* strains are still taken as the most promising candidates for novel antibiotic discovery. In the synthetic biology era, manipulation of regulatory genes has been employed to activate of some cryptic gene clusters.

The production of antibiotic in *Streptomyces* can be largely enhanced by rewiring the regulatory network. There are several reviews on the advances about the elucidation of regulatory networks and the activation of cryptic gene clusters in *Streptomyces* ([@B86]; [@B90]; [@B132]; [@B93]). Antibiotics or specialized metabolites usually means same for secondary metabolites produced by *Streptomyces*. Here, the term antibiotic is used to stand for the natural products. In this review, we will focus on the production enhancement and new antibiotic discovery by manipulation of the regulatory networks in *Streptomyces*. We proposed that the systematic rewiring of regulatory networks in *Streptomyces* would play a critical role in drug discovery and production enhancement in the near future.

The Regulatory Cascades of Antibiotic Production in *Streptomyces* {#S2}
==================================================================

It is commonly recognized that antibiotic production is stringently regulated by pyramidal transcriptional regulatory cascades in *Streptomyces*. Recent years, there were several reviews on the regulatory networks of *Streptomyces* ([@B101]; [@B124]; [@B132]; [@B93]). So here we won't go into detail of the regulatory networks involved in antibiotic production. The regulatory cascades of antibiotic production will be briefly presented from the following four levels.

The first one is the onset of antibiotic production, which is triggered by the coupled receptors of *Streptomyces* "hormones" or other signals. Among them, A-factor, the chemical structural characteristic γ-butyrolactone (GBL), is the first *Streptomyces* hormone reported as a signal triggering streptomycin production in *Streptomyces griseus* in 1967. Avenolide was identified as a new type of butenolide hormone regulating avermectin production in *Streptomyces avermitilis* ([@B52]). The production of the methylenomycin is induced by methylenomycin furan (MMF), a furan-type autoregulator in *Streptomyces coelicolor* ([@B138]). It was reported that 84.1% actinomycetes probably use either GBL (64.1%) or butenolide (24%) to control the antibiotic production ([@B121]). A-factor, coupled with its receptor ArpA, controls transcription of the master positive regulator AdpA for morphological differentiation and streptomycin production in *S. griseus* ([@B38]).

The second level is the global regulators which bring pleiotropic effects on the lower level of regulators. The global regulators affect more than one metabolic pathways and may not directly affect any specific biosynthetic gene clusters (BGCs). They also respond to a variety of chemical or physiological signals, e.g., nutrient limitation, the concentration of chitin or *N*-acetylglucosamine (GlcNAc) in the medium, cell wall damage, heat shock or pH shift. Two-component systems (TCSs, consisted with a membrane-bound histidine kinase, which senses specific environmental stimuli, and a cognate regulator) play crucial roles in sensing extracellular signals. Typical TCSs mediate responses to the cellular signal, mainly through regulating the transcription of downstream genes. Moreover, TCSs, as the most abundant pleiotropic regulators, are involved in the dynamic control of the biosynthesis of secondary metabolites in *Streptomyces*. E.g., PhoP/PhoR can regulate antibiotic production and morphological differentiation ([@B143]; [@B99]). Both antibiotic production and GlcNAc uptake *via* the phosphotransferase system are directly regulated by DasR, a GntR-family allosteric regulator, with the GlcNAc as a ligand ([@B25]). The major checkpoint for the onset of secondary metabolism is the accumulation of GlcNAc through the autolytic degradation of the vegetative mycelium. The antibiotic production is triggered by DasR regulon ([@B98]). AdpA, which is ubiquitously distributed in streptomycetes as a member of the AraC/XylS family regulators, affects transcription of hundreds of genes involved in morphological differentiation and antibiotic biosynthesis ([@B38]; [@B33]). ArpA, the receptor of A-factor, regulated the transcription of *adpA* in *S. griseus*. The transcription level of *adpA* is dynamic controlled by the interaction between ArpA and A-factor. As A-factor reached a threshold concentration, it binds to ArpA and releases the repression of *adpA* transcription ([@B132]). WblA and AtrA also have been extensively investigated as the global regulators involved in the biosynthesis of antibiotic. As a global repressor, WblA affects doxorubicin (DXR), tautomycetin, and daptomycin biosynthesis in their natural host strains ([@B84]; [@B80]; [@B51]). However, WblA activates natamycin biosynthesis in *Streptomyces chattanoogensis* ([@B148]).

The third level is pathway-specific regulators (PSRs), which are taken as the master switches of antibiotic production. PSRs are situated in the BGCs of secondary metabolites and directly regulate the transcription of the biosynthetic genes. So they have been called the "cluster-situated regulators (CSRs)." SARP (*[S]{.ul}treptomyces* [a]{.ul}ntibiotic [r]{.ul}egulatory [p]{.ul}roteins), LAL ([l]{.ul}arge [A]{.ul}TP-binding regulators of the [L]{.ul}uxR family) and PAS-LuxR family regulators usually belong to PSRs ([@B73]). The ActII-ORF4 and RedD of *S. coelicolor* and DnrI of *S. peucetius* are typical SARPs family activators ([@B111]). The LAL family regulators, which comprise an N-terminal ATP/GTP-binding domain and a C-terminal LuxR family DNA-binding domain, usually activate the biosynthesis of antibiotic in *Streptomyces*. PimR, RapH, NysRI, AveR, and SlnR, which are typical LAL regulators, are located in type I polyketide BGCs in *Streptomyces* ([@B3]; [@B105]; [@B53]; [@B32]; [@B155]). The whole process of avermectin biosynthesis is controlled by direct interaction between AveR and all promoters of *ave* cluster ([@B32]). The PAS-LuxR family regulator is characterized with an N-terminal PAS sensory domain and a C-terminal LuxR type DNA binding domain. PAS domain probably function as responsor to light, redox potential, oxygen, overall energy level of a cell, and small ligands ([@B120]). For the cytosol localization, proteins containing PAS domains can sense internal signals and other environmental factors which cross the cell membrane. PimM, a PAS-LuxR family regulator, positively regulates pimaricin production in *Streptomyces natalensis* ([@B4]). The orthologs of PimM have been represented in most of the reported BGCs of antifungal polyketides like amphotericin (AmphRIV), candicidin (FscRI), nystatin (NysRIV), and filipin (PteF) gene clusters ([@B104]). PSRs also contain other family repressor or activator. The production of antibiotic can be positively or negatively regulated by TetR, MarR, LysR, and IclR family regulators ([@B78]; [@B73]; [@B18]; [@B150]; [@B31]).

The fourth level is the feedback regulation which is brought by antibiotic and/or intermediates to coordinate antibiotic production and transport. Evidences have shown that antibiotic functions as signals to regulate the production of antibiotic besides as feedback substances for the enzymatic reactions. Antibiotic, as ligand for proper regulator, affects the final production in *Streptomyces*. The expression of antibiotic biosynthetic genes was modulated by the RedZ and undecylprodigiosin complex ([@B131]). The activity of AtrA, which regulates primary and secondary metabolism, is reduced by lidamycin of *Streptomyces globisporus* and actinorhodin (ACT) of *S. coelicolor* ([@B62]). The biosynthesis of jadomycin is dynamically modulated by the interaction among jadomycin B, chloramphenicol, JadR1 and JadR2 in *Streptomyces venezuelae* ([@B131]; [@B137]). Daunorubicin (DNR) biosynthesis is regulated by three DNA binding regulatory proteins (DnrI, DnrN, and DnrO). The DNA binding activity of DnrO can be modulated by Rhodomycin D, a glycosylated precursor of DXR ([@B47]). Simocyclinone and its precursors inhibit the binding activity of SimReg1 to several promoter regions of simocyclinone biosynthesis genes and SimReg1 encoding gene ([@B41]). As a GBL receptor-like protein, PapR5, which is the major regulator of pristinamycin biosynthesis, may sense pristinamycin or intermediate(s) of the pathway ([@B75]). SsaA can activate sansanmycin biosynthesis by binding to five different regions within the sansanmycin BGC. The sansanmycins A and H inhibit DNA-binding activity of SsaA in a concentration-dependent manner ([@B60]). The rifamycin B, the end product of rifamycin biosynthesis, can relieve the repression of RifQ on the transcription of the rifamycin efflux pump (RifP) ([@B58]). Transporters may affect product maturation. The ABC transporters NysG and NysH involved in the biosynthetic export of nystatin in *Streptomyces noursei*. Deletion of either transporter gene caused ca. 35% reduction in the levels of fully formed nystatin and led to concomitant enrichment of a deoxy precursor. The authors proposed that a NysGH complex might preferentially export fully formed nystatin and that this activity would increase the efficiency of the last biosynthetic step through product removal ([@B109]). For both class I and II lantibiotics, the function of a dedicated ABC transporter, generally termed 'LanT,' is essential for the formation of the final product ([@B27]).

Signals and regulators, dynamic fluctuating on the metabolic state of the cell and its environment, are extensively involved in regulation of secondary metabolism. The abundances of nitrogen, phosphate and carbon sources are nutrimental signal for the onset of secondary metabolism. It has been reported that GlnR and PhoR--PhoP was involved in the type of regulation depending on the carbon, nitrogen, and phosphate supply. For the similarity of binding sites, PhoP and GlnR showed competitive binding to target genes in some cases ([@B101]). In *Saccharopolyspora erythraea*, the GlnR regulon is not only involved in nitrogen metabolism, but it also appears to control ABC-type transporters for uptake of carbon sources ([@B63]). In *S. avermitilis*, AveR positively regulates avermectin production and negatively affects oligomycin biosynthesis, respectively ([@B32]). AveI, an AtrA-like regulator, regulates production of avermectin, oligomycin, melanin, and morphological differentiation by directly regulating the transcription of *ave*, *olm*, *melC1C2*, *ssgRD*, *wblI* and genes in primary metabolism, including substrates transport, the metabolism of amino acids, lipids, and carbohydrates ([@B66]). Usually more than twenty secondary metabolic pathways exist in most of the *Streptomyces* ([@B82]). There is complex cross-talk regulation among different biosynthetic clusters and between the primary and secondary metabolism. With the deep understanding the regulatory mechanism of the antibiotic production, there is a consensus that the complicated and interweaved regulatory networks contribute to the dynamic antibiotic production in *Streptomyces*.

Enhancement of Antibiotic Production in *Streptomyces* by Rewiring the Regulatory Networks {#S3}
==========================================================================================

As mentioned above, the regulatory networks constitute major bottlenecks to over produce target antibiotics. The manipulation of regulatory genes can contribute to overcome these bottlenecks to turn on the expression of gene clusters for antibiotic production. Various strategies have been taken to manipulate regulatory genes to achieve the optimal antibiotic production in both the native and/or heterologous hosts.

Enhancing Antibiotic Production by Overexpression of Positive Regulator Genes {#S3.SS1}
-----------------------------------------------------------------------------

The regulators also can be defined as positive and negative regulators according their effect on the antibiotic production. The positive regulators (activators) can promote the biosynthesis of antibiotics. But the negative ones (repressors) can repress the biosynthesis of antibiotics ([@B72]). Since the positive regulators activate the transcription of antibiotic BGCs, they can be manipulated to enhance the production of antibiotic in *Streptomyces*. The titer improvement can efficiently and simply be achieved by over-expression of genes encoding activators with proper promoters. As listed in [Table 1](#T1){ref-type="table"}, overexpression of genes encoding LAL family regulators, such as MilR, NemR, and AveR, has been used to increase production of milbemycin in *S. bingchenggensis* BC04, nemadectin in *S. cyaneogriseus* subsp. *non-cyanogenus* NMWT1 and avermectin in *S. avermitilis*, respectively ([@B32]; [@B151]; [@B59]). Overproduction of nikkomycin has been achieved by engineering of the CSR activator gene *sanG* with different constitutive promoters ([@B65]). Overproduction of oxytetracycline (OTC) has been achieved by overexpression of the CSR activator gene *otcR* as tandem copies under the control of a constitutive SF14 promoter ([@B144]). Similar strategy has also been used to overproduce tacrolimus (FK506) in *Streptomyces tsukubaensis* NRRL18488 by overexpression of *bulZ* ([@B68]). Other examples include LysR family regulator for ascomycin production in *S. hygroscopicus* var. *ascomyceticus* ([@B112]), PAS-LuxR family regulator for wuyiencin production in *Streptomyces wuyiensis* CK-15 ([@B67]), and Crp/Fnr family regulator for leinamycin production in *Streptomyces atroolivaceus* ([@B45]).

###### 

Examples of antibiotic production enhancement in *Streptomyces* by regulatory gene manipulation.

  **Strategy**                               **Antibiotics**   **Strains**              **Regulators (family)**   **Yield**   **References**
  ------------------------------------------ ----------------- ------------------------ ------------------------- ----------- ----------------
  Overexpression of positive genes           Milbemycin        *S. bingchenggensis*     MilR(LAL)                 138%        [@B151]
                                             Nemadectin        *S. cyaneogriseus*       NemR(LAL)                 179.9%      [@B59]
                                             Avermectin        *S. avermitilis*         AveR(LAL)                 164%        [@B32]
                                             Nikkomycin        *S. ansochromogenes*     SanG(SARP)                200%        [@B65]
                                             Oxytetracycline   *S. rimosus*             OtcR(SARP)                649%        [@B144]
                                             FK-506            *S. tsukubaensis*        BulZ (SARP)               ∼330%       [@B68]
                                             Wuyiencin         *S. ahygroscopicus*      WysR(PAS-LuxR)            300%        [@B67]
                                             Leinamycin        *S. atroolivaceus*       LnmO(Crp/Fnr)             300%        [@B45]
                                             Pimaricin         *S. natalensis*          PimM(PAS-LuxR)            240%        [@B4]
                                             Pimaricin         *S. chattanoogensis*     ScnRII(PAS-LuxR)          400%        [@B23]
                                             Milbemycin        *S. hygroscopicus*       MilR2 (TetR)              34.4%       [@B133]
                                             Avermectin        *S. avermitilis*         SAV4189 (MarR)            250%        [@B31]
                                             FK-506            *S. tsukubaensis*        FkbN (LAL)                176%        [@B152]
                                             Daptomycin        *S. roseosporus*         DepR1(TetR)               141%        [@B149]
                                             Daptomycin        *S. roseosporus*         DptR3(*MarR)*             131%        [@B150]
  Deletion of negative regulatory genes      Avermectin        *S. avermitilis*         SAV151(TetR)              200%        [@B35]
                                             Calcimycin        *S. chartreusis*         CalR3(TetR)               280%        [@B29]
                                             Pristinamycin     *S. pristinaespiralis*   PapR3(TetR)               240%        [@B77]
                                             Daptomycin        *S. roseosporus*         WblA                      151%        [@B44]
                                             Pikromycin        *S. venezuelae*          WblA                      350%        [@B135]
                                             Doxorubicin       *S. peucetius*           WblA                      170%        [@B84]
                                             Platensimycin     *S. platensis*           PtmR1(GntR)               ∼500%       [@B110]
                                             Natamycin         *S. natalensis*          PhoRP(TCS)                180         [@B76]
                                             Milbemycin        *S. bingchenggensis*     NsdA                      150%        [@B129]
                                             Natamycin         *S*. *lydicus*           NsdA                      190%        [@B136]
                                             Avermectin        *S. avermitilis*         AveI(AtrA)                1600%       [@B14]
                                             Nystatin A1       *S. ahygroscopicus*      TtmRIV(PAS-LuxR)          212%        [@B17]
                                             Rapamycin         *S. rapmycinicus*        RapS(TetR)                460%        [@B146]
                                             Rapamycin         *S. rapmycinicus*        RapY(TetR)                370%        [@B146]
  Deletion of GBL receptors                  Tylosin           *S. fradiae*             TylP                      ∼200%       [@B113]
                                             Avermectin        *S. avermitilis*         AvaR1                     ∼300%       [@B127]
                                             Milbemycin        *S. bingchenggensis*     SbbR                      125%        [@B36]
                                             Natamycin         *S. natalensis*          SngR                      460%        [@B57]
                                             FK506             *S. tsukubaensis*        BulR1                     27.8%       [@B102]
                                             Clavulanic acid   *S. clavuligerus*        Brp                       300%        [@B103]
                                             Validamycin       *S. hygroscopicus*       ShbR1/R3                  ∼55%        [@B117]
  Overexpression the feedback transporters   Avermectin        *S. avermitilis*         AvtAB                     ∼50%        [@B95]
                                             Daunorubicin      *S. peucetius*           *DrrC*                    510%        [@B71]
                                             Rifamycin         *A. mediterranei*        *RifQ*                    200%        [@B58]
  Ribosomal engineering                      Avermectin        *S. avermitilis*         σ^hrdB^(A56 A393)         150%        [@B156]
                                             Actinorhodin      *S. lividans*            RpsL(K88E, L90K)          290%        [@B89]
                                             Actinorhodin      *S. coelicolor*          K88E, the GI92            200%        [@B130]
                                             Salinomycin       *S. albus*               RpsL(K88R), RpoB          230%        [@B116]
                                             A21978C           *S. roseosporus*         RpsL K43N                 220%        [@B128]
                                             Chloramphenicol   *S. coelicolor*\*        RpsL(K88E) RpoB(S433L)    ∼1000%      [@B28]

\*Heterologous expression.

The expression level of positive regulator is not always correlated to the production of antibiotic. E.g., overexpression of *mil*R with a strong constitutive promoter led to decrease of milbemycin production in *S. bingchenggensis* ([@B151]). These showed that the threshold of the over-expressed regulator was key point to determine the production of antibiotic in *Streptomyces*.

Enhancing Antibiotic Production by Removal of Repressor Genes {#S3.SS2}
-------------------------------------------------------------

The TetR and LysR family regulators are widely distributed in the genome of *Streptomyces*. Most of TetR and LysR regulators function as repressors. More details of TetR family regulators have been reviewed elsewhere ([@B18]). Deletion of TetR family repressors has been used to increase avermectin production in *S. avermitilis* ([@B35]), calcimycin production in *Streptomyces chartreusis* NRRL 3882 ([@B29]), and pristinamycin production in *Streptomyces pristinaespiralis* ([@B77]).

WblA, a WhiB-like protein, also widely distributes among actinomycetes ([@B51]; [@B44]). WblA affects morphological development and antibiotic biosynthesis. It generally functions as a global repressor of antibiotic biosynthesis, such as DXR biosynthesis in *S. peucetius*, tautomycetin biosynthesis in *Streptomyces* sp. CK4412, and daptomycin biosynthesis in *Streptomyces roseosporus*. Deletion of *wblA* leads to overproduction of pikromycin in *S. venezuelae* ([@B135]), daptomycin in *S. roseosporus* ([@B44]). Other examples include deletion of genes encoding GntR family regulators for platensimycin and platencin overproduction in *Streptomyces platensis* ([@B110]).

The *nsdA*, a gene negatively affecting *Streptomyces* differentiation, had been proved a pleiotropic negative regulatory gene in *S. coelicolor* ([@B61]). It plays a negative role in sporulation, morphological differentiation and antibiotic synthesis. The overproduction of ACT, calcium-dependent antibiotic (CDA), and methylenomycin was detected in a *nsdA* mutant. The *nsdA* homologous genes have been found to conservatively distribute in *Streptomyces*. The milbemycin A4 and nanchangmycin production increased in *nsdA* mutant of *S. bingchengensis* by 1.5-fold and 9-fold, respectively ([@B129]). The natamycin production can be increased 1.9-fold by deletion of *nsdA* gene in *Streptomyces lydicus* A02 ([@B136]).

γ-Butyrolactone receptors, like the A-factor receptor ArpA, repress transcription of *adpA* to affect the production of streptomycin in *S. griseus*. Deletion of the GBL receptors probably can promote antibiotic production. The validamycin production of mutants with deletion of *arpA* homologs were increased by 26% (Δ*shbR1*) and 20% (Δ*shbR3*) in *S. hygroscopicus* 5008, respectively ([@B117]). Deletion of *avaR1*, the avenolide (a novel butenolide-type autoregulator) receptor encoding gene, increased production of avermectin B1a approximately 1.75 times compared with the parent strain in a high-producing *S. avermitilis* strain ([@B127]).

Enhancing Antibiotic Production by Manipulation of Feedback and Transport {#S3.SS3}
-------------------------------------------------------------------------

Genes encoding exporters, which are responsible for the secretion of antibiotic, often situate in their BGCs. The majority of BGC-linked antibiotic exporters belongs to various subgroups like the ATP-binding cassette (ABC) superfamily and major facilitator superfamily (MFS) of transporters. It is commonly assumed that BGC-linked exporters function in the secretion of the antibiotic made by BGC. Toxic end-products can be pumped out of the cells by exporters to realize more durable and sustainable productivity.

Importantly, even in the absence of toxicity, the ability to secrete the end-products may play key roles in affecting the expression of the BGCs. ActA (ActII-ORF2) and ActB (ActII-ORF3) are MFS and RND (root-nodulation-division) exporters, respectively, involved in ACT production in *S. coelicolor*. ActA and ActB are crucial players in the sophisticated feed-forward mechanism, by which secretion of the end-products leads to the transcriptional activation of the BGCs in the cells ([@B114]; [@B140]). The double *actAB* mutant could only produce one fifth of ACT compared to WT. The activation of ACT production occurs in two waves where expression of key *act* genes, including the *actAB* operon, is initially induced by a biosynthetic intermediate. The ACT production grows into full induction only once the accumulating ACT is secreted out of the cells.

The genes encoding for the AvtAB ABC transporter are adjacent and co-expressed with the BGC for avermectin in *S. avermitilis*. In the WT strain, deletion of either *avtA* or *avtB* had no effect on avermectin production, while over-expression of *avtAB* led to the increased level of avermectin B1a with two-fold. But the production level of oligomycin A, another product from *S. avermitilis*, was found unaltered. The production promotion effects of *avtAB* could be specific to avermectin in *S. avermitilis* ([@B95]). Co-overexpression of three OTC resistance genes, including *otrA* (encoding a ribosomal protection protein), *otrB* and *otrC* (encoding two efflux proteins), led to 179% increase of OTC production in *Streptomyces rimosus* M4018 ([@B145]).

Feed-forward mechanisms may explain the regulation of BGCs for the actinobacterial ribosomally synthesized and post-translationally modified peptides (RiPPs), planosporicin and microbisporicin. The multiple ABC transporter genes in these BGCs seem to modulate their production and self-immunity ([@B26]; [@B108]). GouM, the MFS transporter, is responsible for the secretion of gougerotin outside of *Streptomyces graminearus* ([@B134]). The overexpression of BotT, a putative efflux pump encoded in the bottromycin BGC, increased bottromycin production about 20 times in a heterologous host ([@B46]).

Export of antibiotic is important for the producer to reduce the intracellular antibiotic concentration, which can relieve self-toxicity. In *Amycolatopsis mediterranei*, Δ*rifQ* mutant brought overexpression of RifP. The accelerated export of rifamycin may reduce the intracellular rifamycin concentration, relieve other possible feedback inhibition of rifamycin biosynthesis and finally lead to more than two-fold improvement of rifamycin B production ([@B58]). Overexpression of DrrC, which provide self-resistance to DNR and DXR, achieved 5.1-fold increase in DXR production in *S*. *peucetius* ATCC 27952 ([@B71]).

For there are many transporters help to transport end products or intermediates out of the cell, this can help to remove the feedback caused by the antibiotics or intermediates. Transporters enhance the efflux of the self-produced antibiotics, which can be an important strategy for self-protection from self-toxicity. Many antibiotic BGCs comprise functional exporter genes ([@B96]; [@B106]). Also some exporters encoding genes for detoxification are outside of the BGCs. By systematical investigation, it has proved that more than 25 groups of genes contributed the efflux of molecules involved in natamycin biosynthesis ([@B107]).

Enhancing Antibiotic Production by Ribosome Engineering {#S3.SS4}
-------------------------------------------------------

Classical strain improvement is usually achieved by multiple rounds of random mutagenesis and repetitively screening. Although the outcome is fruitful, the weakness of this strategy is time intensive and laborious. A ribosome engineering approach has been designed to obtain antibiotic overproducing strains by corelatively screening for mutants with proper drug resistant level, e.g., streptomycin resistance mutations ([@B43]). It has been proven to be an effective rational strategy for strain improvement. The percentage of overproducing mutants among drug resistance mutants can be up to 2--20% in a species dependent way, which is much higher than that of random mutagenesis. S12-mutated variants, which have mutations in the *rpsL* gene with resistance to streptomycin, stabilize the open A-site conformation and prevent streptomycin from binding ([@B39]). Screening of streptomycin resistant mutations has been demonstrated a useful tool for strain improvement in many *Streptomyces* strains ([@B85]). The undecylprodigiosin production in *S. lividans* was activated in RpsL mutants with K88E, L90K, and R94G substitutions ([@B89]). The industrial strain of *S. albus*, which had RpsL (K88R) and RpoB mutation, enhanced salinomycin production by 1.5-fold ([@B116]). In *S. coelicolor*, over 10-fold ACT improved in RpsL (K88E and P91S) strains than the original strain ([@B88]). Both the K88E mutation and an insertion mutation at GI92 led to substantially higher levels of ACT in *S. coelicolor* strains ([@B130]). Selection of mutations in the *rpsL* gene are widely used to improve the production in a variety of industrial antibiotic-producing strains ([@B116]; [@B8]).

Another method of "ribosome engineering" incorporates the inactivation of the *rsmG* gene, which encodes an *S*-adenosylmethionine (SAM)-dependent 16S rRNA methyltransferase. Recombinants with deletion of *rsmG* gene resulted in overproduction of ACT in *S. coelicolor* ([@B83]).

Previous reports showed that ribosome engineering was an effective strategy for yield improvement in *Streptomyces*. From the reference, ribosome engineering has been employed for yield improvement in more than fifty *Streptomyces* strains ([@B154]). As a rational and cost-effective approach, ribosome engineering could be adapted to speed up strain development for those without clear genetic background. If compared with other direct genetic manipulation approach, the ribosome engineering still be with laborious screening to overcome the phenotype uncertainty of resistant mutants.

The above data show that manipulation of regulatory cascades can be an efficient way to improve the production of antibiotic. It is obvious that the balance and synergy between primary and secondary metabolism is very important for the overproduction of antibiotic. Rewiring regulatory network combined with metabolic engineering will be a more powerful way to enhance the production of antibiotic in *Streptomyces*.

Discovering Novel Antibiotics Through Activating the Cryptic Gene Clusters by Unlocking Their Regulatory Network {#S4}
================================================================================================================

The genome sequencing of streptomycetes demonstrated that each genome has the genetic capacity with 20--40 distinct gene clusters for secondary metabolites. They can produce far more compounds than reported previously ([@B82]). Since many of these gene clusters are expressed at low levels under laboratory conditions, they are called cryptic gene clusters. Several strategies have been designed to activate these clusters and discover novel molecules. The feasible approaches include uses of signals probes, ribosome engineering, regulatory unlocking and heterologous expression ([@B54]; [@B86]; [@B79]). For this review is about the regulation in *Streptomyces*, the heterologous expression will not be discussed here.

Activation of Cryptic Gene Clusters by Chemical or Physical Signals {#S4.SS1}
-------------------------------------------------------------------

Though *Streptomyces* has the potential to produce over 20 secondary metabolites, most BGCs are cryptic or silent. As we know from the regulatory cascades, there are many signaling factors affecting the expression of secondary metabolic gene, and many culture dependent methods have been developed ([@B147]).

The one strain many compounds (OSMACs) approach has been previously applied to explore the secondary metabolic potential of different strains with altering a single parameter in the growth conditions or eliciting a stress response ([@B10]). Heat shock and ethanol shock are two widely applied measures. *S. venezuelae* produces negligible amounts of jadomycin when it is cultured at 27°C without heat/ethanol shock. The yield of jadomycin B reach 25 μg/ml after 12 h by shifting the temperature from 27 to 42°C. Similarly, cultures with 6% ethanol enhanced yields of jadomycin to as high as 30 μg/ml at 27°C ([@B21], [@B22]). Another compound that is produced in response to the heat/ethanol shock is validamycin A (VAL-A) by *Streptomyces hygroscopicus*. VAL-A rapidly accumulated at relatively higher fermentation temperatures (37°C, 40°C, and 42°C). But the production was very low at lower temperatures (28°C, 30°C, 33°C, and 35°C) ([@B64]). Several other stress responses have been explored. New metabolites can be produced by *Streptomyces parvulus* upon increasing the hydrostatic pressure during fermentation ([@B10]). *S. coelicolor* can produce ectoine and 5-hydroxyectoine under high salt conditions and temperature stress ([@B12]). Methylenomycin production can be activated in *S. coelicolor* by either alanine growth-rate-limiting conditions and/or acidic pH shock ([@B34]).

As we know that the autoregulators can trigger the antibiotic production in *Streptomyces*. These classes of naturally produced chemical probes like GBLs can be used to elicit the expression of cryptic SBGs. Goadsporin, a compound isolated from *Streptomyces* sp. TP-A0584, was shown to stimulate the production of prodiginine antibiotic in *S. lividans*, and promote pigment production and morphogenesis on 36 streptomycetes ([@B92]).

In *Streptomyces*, antibiotic production, which is usually coupled with the onset of development, is triggered by the interaction between DasR and the accumulation of GlcNAc after autolytic degradation of the vegetative mycelium. So GlcNAc can be used as a signal chemical to activate pathways for secondary metabolite biosynthesis. Several *Streptomyces* species were examined for their antibiotic production on MM plates (25 mM mannitol as the sole carbon source) with or without GlcNAc (50 mM). GlcNAc had a stimulating effect on antibiotic production on *S. clavuligerus*, *S. collinus*, *S. griseus*, *S. hygroscopicus*, and *S. venezuelae* ([@B98]).

By investigating small molecules that perturb secondary metabolism, Justin group had screen out 19 compounds from 30,569 small molecules of the Canadian Compound Collection for their ability to alter the pigmentation of *S. coelicolor.* The ARC2 series (ARC2, ARC3, ARC4, and ARC5) were structurally related to triclosan, a synthetic antibiotic ([@B16]). Particularly, ARC2 altered the secondary metabolite output in all of the tested streptomycetes ([@B16]; [@B2]). These probes appear to have the potential to widely use as active elicitors for mining secondary metabolite.

Since *Streptomyces* is the soil dwelling microbe, it was reported that antibiotic overproduction could be promoted by 2- to 25-fold when the rare earth, scandium (Sc), added at a low concentration (10--100 mM) to cultures of *S. coelicolor* A3(2) (ACT producer), *Streptomyces antibioticus* (actinomycin producer), and *S. griseus* (streptomycin producer). Scandium was also effective in activating the dormant ability to produce ACT in *S. lividans* ([@B50]). The rare earth elements, scandium and/or lanthanum, can activate the expression of nine genes belonging to nine secondary metabolite--BGCs by 2.5- to 12-fold in *S. coelicolor* A3(2). Several compounds can only be detected with HPLC in the rare earth-treated cultures ([@B118]).

Combined-culture is a co-culture method to activate secondary metabolism in *Streptomyces* ([@B90]). The biosynthesis of red pigment by *S. lividans* TK23 can be influenced by co-culture with *Tsukamurella pulmonis* TP-B0596. It was proved that the biosynthesis of cryptic natural products in *Streptomyces* species can only be induced by living mycolic acid-containing bacteria (MACB). ∼90% of *Streptomyces* species, which isolated from soil samples collected in the Hokuriku district of Japan, show changes in secondary metabolism in combined-culture with *T. pulmonis* ([@B91]).

Binding to a specific receptor, like the A factor, is proposed as possible mechanisms of activation of secondary metabolite biosynthesis by some chemical probes. The perturbation of host metabolism can be another reason to activate cryptic clusters. The ARC2 series, similar to triclosan, repress fatty acid biosynthesis by inhibiting the enoyl reductase FabI and change the flux of precursor molecules to antibiotic biosynthesis. Quorum sensing molecules could also important factors to induce the secondary metabolite production in actinomycetes. The results from co-cultivation probably due to physical cell to cell interactions, small molecule-mediated communication or metabolite precursor supply ([@B1]; [@B49]). Though a great many of products are discovered through activation of cryptic gene clusters by chemical or physical signals, it still lacks clearly explanation of the molecular mechanism triggering the expression of the secondary metabolic genes. But for this approach is non-genetic dependent, it can be developed to high-throughput screening model to investigate more strains easily.

Activation of the Cryptic Gene Clusters by Manipulation of the Regulatory Genes {#S4.SS2}
-------------------------------------------------------------------------------

The transcription processes of BGCs are usually modulated by specific regulatory gene clusters, including activators and repressors, which activate or repress biosynthesis, respectively. The identification of PSRs genes offers possibility to activate the desired BGCs either by inactivation of the repressor or over-expression of the activator genes ([@B7]).

TetR family of transcription regulators, which participate in the regulatory pathways associated with the efflux of antibiotic, cell--cell signaling, antibiotic biosynthesis, biofilm formation, etc., is one of the most predominant families of transcription factors in the prokaryotic system ([@B9]). The TetR family members usually serve as repressors which possess a N-terminal DNA-binding domain and a C-terminal signal reception domain ([@B18]). The inactivation of a TetR transcriptional repressor gene *arpRII* in *Streptomyces argillaceus* promoted the activation of the cryptic gene cluster *arp*, and discovery of argimycins P, a natural product in polyketide alkaloid family ([@B142]). ScbR, another TetR-like transcriptional repressor, has been confirmed to directly control the expression of the cryptic type I polyketide BGC by binding at two different positions of *kasO* promoter in *S. coelicolor* ([@B115]; [@B137]; [@B9]). GdmRIII, a TetR family transcriptional regulator, was connected with the biosynthetic pathways of geldanamycin and elaiophylin in *Streptomyces autolyticus* CGMCC0516 ([@B48]). Moreover, it has been proved that the biosynthetic pathways including jadomycin, kinamycin, and auricin, were activated after removal of TetR family repressors, JadR/JadR2 ([@B153]), AlpW ([@B11]), and SCO1712 ([@B55]), respectively.

LuxR superfamily is another predominant class of regulators associated with quorum sensing ([@B7]). Contrary to the TetR family, LuxR-like proteins usually act as activators during secondary metabolic regulation. LuxR proteins consist of an N-terminal DNA binding domain and a C-terminal ligand-binding domain, where ligand binding induces homo-dimerization and subsequent binding of protein to DNA to initiate transcription ([@B69]). LuxR proteins, which are abundant among Actinobacteria, Proteobacteria, and Firmicutes, play significant roles in improvement of antibiotic production and activation of cryptic gene clusters after overexpression. The LuxR family members, GdmRI and GdmRII, are positive regulators required for geldanamycin biosynthesis in *S. hygroscopicus* 17997, and inactivation of them resulted in blocked production of geldanamycin ([@B37]). The synthesis of β-lactam antibiotic thienamycin was first observed when ThnI protein of LuxR family was induced in *Streptomyces cattleya* ([@B100]). Furthermore, the LAL--proteins are large ATP-binding regulators constituting a noteworthy branch of LuxR family ([@B20]). The LAL--subfamily members usually contain an additional ATP binding domain at the N-terminus, which is responsible for the interaction with the inducers, maltotriose and ATP ([@B19]; [@B7]). Series of studies have confirmed that LAL regulators play important roles in activating the silent gene clusters. Overexpression of LAL-type regulatory factor *samR* in *Streptomyces ambofaciens* activated a 150 kb cryptic gene cluster, and promoted the discovery of a glycosylated macrolide product with anti-cancer activity ([@B54]). Similarly, LAL-type transcriptional regulators of GdmRI and GdmRII in *S. hygroscopicus* are positive to geldanamycin biosynthesis ([@B74]). Furthermore, the LAL-like 63-amino acid protein AfsS and its homologs have been shown to relate closely with the induction of avermectin in *S. avermitilis* ([@B56]), pikromycin in *S. venezuelae* ([@B70]), and DXR in *S. peucetius* ([@B94]).

Manipulation of the regulators in cryptic gene clusters probably the most convenient way to activate the pathway. But for the uncertainty of regulatory network, the success of activation is case by case.

Activation the Cryptic Gene Clusters by Ribosome Engineering {#S4.SS3}
------------------------------------------------------------

Ribosome engineering, first proposed by Kozo Ochi, focuses on modifying ribosomal or RNA polymerases whose structural and functional changes related to the synthesis of secondary metabolites ([@B87]). The introduction of specific mutations into the ribosome elements triggers structural changes to ribosome with affected protein synthesis, which ultimately influences secondary metabolism of the microorganism. Targeted strains are screened by mutations in antibiotic resistance acting on ribosome without special requirement of equipment or genetic background of the strains. Isoindolinomycin (Idm), an unprecedented bioactive polyketide with a novel isoindolinone-containing tetracyclic skeleton, was discovered by activation of cryptic gene through screening rifampicin-resistant (*rif*) mutants from actinobacteria strains ([@B122]). Piperidamycins production was induced in a gentamicin-resistant mutant of *Streptomyces mauvecolor*, whereas the wild strain does not produce these metabolites at any detectable level on various media ([@B42]; [@B7]). Ribosome engineering now is developed into an important technology for improving secondary metabolites with commercial value and stimulating new natural product production, and also contributes to increase in structural diversity of bioactive compounds. Mutations in these ribosomal genes have also been shown to activate the expression of silent or poorly expressed BGCs in *S. griseus* ([@B119]).

Most above strategies to activate cryptic gene clusters are by manipulating the original host. With developing of large DNA cloning, heterologous expression is extensively used to overexpress target clusters in super host strains ([@B141]; [@B30]; [@B15]). There are series of reviews on this aspect. Also some heterologous expression was solved with overexpression of regulatory genes by proper promoters in the target clusters ([@B24]; [@B79]; [@B81]; [@B139]).

Conclusion and Perspectives {#S5}
===========================

*Streptomyces*, which has complex morphological development and cell differentiation, can adapt to diverse environments by ingenious regulation and produce variety of secondary metabolites. The regulation of antibiotic production has been extensively investigated in the past years. For the complicated interactions among primary and secondary metabolic pathways, elucidation of the regulatory network in antibiotic production still was a tough task for scientist. With further recognizing the secondary metabolism regulatory cascades, novel proposed strategies can greatly promote the production enhancement and drug discovery in *Streptomyces*. For there are several reviews on the regulation of antibiotic biosynthesis, strategy to enhance production of antibiotic in *Streptomyces* and new compounds discovery in actinobacteria by Nodwell group and van Wezel group ([@B125]; [@B147]; [@B97]; [@B124]). Here we drafted a review on the cascades of regulation and its application in production enhancement and compound discovery ([Figure 1](#F1){ref-type="fig"}). We proposed to give an extensive review on the regulation of antibiotic production in *Streptomyces*.

![Schematic diagram of application strategies for regulatory cascades in *Streptomyces*. The regulatory cascades are illustrated with arrow linked rectangles. The dash circles are annotated with bold text to describe the strategies employed to enhance antibiotic production or discovery of novel antibiotics. The bold arrows mean overexpression of positive regulators. The crossed perpendicular lines mean the deletion of repressors or inhibition of feedback reactions. The dash bold arrows mean enhanced supply of precursor or efflux of antibiotics.](fmicb-11-00406-g001){#F1}

The complex hierarchical regulation constitutes a major bottleneck to over produce target antibiotic. On the basis of understanding the regulation of antibiotic biosynthesis, rewiring the regulatory network is much more efficient to optimize antibiotic producers than the classical random mutagenesis methods. It has mentioned above that the enhancement of antibiotic titers can be achieved by overexpression of positive regulator, inactivation of negative regulator, tuning feedback and ribosomal engineering. Combination of different strategies to manipulate regulatory genes can achieve higher antibiotic production in both the native and/or heterologous host. It is necessary to achieve maximal level of antibiotic production by systematically rewiring the regulatory network.

With the accumulation of explosive genome sequencing data, it has been estimated that *Streptomyces* species harbor a huge unexploited potential to produce novel natural products. A new discovery approach-microbial genome mining has been well developed in the past years ([@B6]). How to efficiently activate cryptic gene clusters is still challenging to scientist. Because the interweaved regulatory networks in most cases are not well studied or understood. Elucidation of the regulatory network is crucial to discover new antibiotics.

For efficient manipulation of the regulatory genes, multi-*loci* simultaneous editing technology is necessary to be invented. The recent application of CRISPR-Cas9 dependent serials genome editing system provides a new opportunity for rapid rewiring regulatory network in *Streptomyces* ([@B123]). For precisely tuning the transcription level of regulators, a panel of quantitative promoters should be defined in *Streptomyces*. This would be practical for tuning the expression of secondary metabolic pathway. Though there are many publications on promoter engineering in *Streptomyces*. Still serial quantitative promoters are necessary for predictable engineering with synthetic biology strategy in future.

Author Contributions {#S6}
====================

HX, XL, ZL, and XZ prepared material for the manuscript. HX, XM, and YL wrote the manuscript. All authors read and approved the final manuscript.

Conflict of Interest {#conf1}
====================

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Funding.** This study was funded by the Natural Science Foundation of Zhejiang Province to HX (LY19C010002).

The assistance of the colleagues of Institute of Biopharmaceuticals during preparing manuscript is gratefully acknowledged.

[^1]: Edited by: Yvonne Mast, German Collection of Microorganisms and Cell Cultures GmbH (DSMZ), Germany

[^2]: Reviewed by: Gang Liu, Institute of Microbiology (CAS), China; Gong-Li Tang, Shanghai Institute of Organic Chemistry (CAS), China

[^3]: This article was submitted to Microbial Physiology and Metabolism, a section of the journal Frontiers in Microbiology
